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The present paper thus summarizes the key information regarding HSCT in the main inherited BMF.
Fanconi anemia (FA)
Although Fanconi anemia (FA) is the most frequent IBFM syndrome, this syndrome is a rare, phenotypically heterogeneous, inherited disorder clinically characterized by congenital abnormalities (renal, cardiac, bone, ear, etc.…), progressive BMF and a predisposition to develop malignancies [3] . More than 18 FA genes have been identified, the most frequently seen being FANCA, FANCC, FANCG, and FANCD2 [4, 5] . BRCA2/FANCD1 and PALB2/ FANCN mutations, who tend to develop MDS, AML and/ or solid cancers (particularly Wilms' tumors and medulloblastomas) very early during childhood are responsible of the more severe forms of this syndrome. HSCT still represents the only curative option for BMF in FA [6] [7] [8] [9] , but still exposed patients to a higher risk of secondary cancers [10] [11] [12] . FA physicians have agreed on consensus treatment guidelines for severe BMF or transformation: persistent hemoglobin <8 g/dL, platelets <30,000/mm 3 , absolute neutrophil count <500/mm 3 , overt leukemia with at least 20 % blasts in the marrow, or morphologic MDS. Adapted conditioning regimens with reduced doses of cyclophosphamide (with or without limited field radiotherapy), have cured FA related BMF in numbers of patients transplanted from a matched related family donor [6, 13, 14] . Published results on unrelated donor (UD) HSCT were less encouraging for long time, mainly because of an increased risk of graft failure, as well as higher incidences of both acute and chronic graft-versus-host disease (GvHD) [7, 15, 16] . However, better results have been recently reported in this setting [17, 18] with 94 % 5-year overall survival in the recent paper from MacMillan in patients transplanted without a history of opportunistic infections or transfusions. The use of fludarabine-based reduced intensity conditioning regimens with or without T-cell depletion seems to contribute to this improvement [8, 9, [18] [19] [20] [21] [22] .
The optimal time for HSCT is probably when transfusion dependency occurs and prior to 20 red cell and/or single platelet transfusions, before androgen therapy, and before the development of clonal evolution (MDS or leukemia). All patients should undergo a bone marrow aspirate with cytogenetic evaluation every year to detect early dysplastic changes or cytogenetic abnormalities [23] .
To avoid transfusions, standard risk patients (<18 years of age, good organ function, absence of advanced MDS or leukemia) should undergo HSCT when persistent and moderately severe cytopenia develops (i.e., hemoglobin <8 g/ dL; absolute neutrophil count <0.5 × 10 9 per liter; and/or platelet count <30 G/l). Patients with evidence of advanced MDS or leukemia should also be considered. Earlier transplantation may be considered for patients with specific mutations deemed to be particularly high risk for rapid progression to MDS or leukemia and poor survival (e.g., -7 or -3q cytogenetic abnormalities or presence of biallelic breast cancer [BRCA] gene mutations).
A matched sibling donor is still the best choice, although significant improvement has been reported with unrelated donor transplantation in the more recent era, especially from 8/8 matched unrelated donor [8, 9, 17, 20] . Related 6/6 matched cord blood is also a reasonable option. Every related donor has to be systematically tested for FA before HSCT schedule. Unrelated 6/6 matched cord blood might be considered in case of more than 3 × 10 7 nucleated cells per kilogram before freezing [24] . Mismatch unrelated donors (less than 10/10), haplo-identical HSCT, as well as the use of 1 or 2 cord blood units with 1 or 2 HLA-disparities regardless of the number of cells should be done in experimented centers within clinical prospective trials only.
Regarding the source of stem cells, bone marrow has been shown to be superior to peripheral blood in patients with acquired aplastic anemia undergoing a matched sibling or unrelated transplant [25] [26] [27] . Similar results have been recently published regarding patients with FA [17, 20] . These results are important enough to consider marrow as the recommended source of stem cells in this particular population.
Preparative regimens for HSCT in patients with FA have been modified from standard approaches because of the chromosomal instability present in all FA cells, including non-hematopoietic tissues. A reduced intensity conditioning regimen has to be used with reduced-dose cyclophosphamide (20-40 mg/Kg total dose) to prevent toxicity. The use of fludarabine with or without T-cell depletion contributed to the significant improvement observed in the recent period [8, 9, 18, 19, 21, 22, 28] . Irradiation should not be added to avoid an additional risk factor interacting with the main biologic defect of FA (i.e., DNA repair processes). However, low-dose Total Body Irradiation (i.e., TBI 2-3 grays) may be used in specific situations with a high risk of rejection (high burden transfusion history and unrelated donors). Historically, the prognosis appears (very) poor for patients with clonal evolution (i.e., myelodysplastic syndrome, acute myeloid leukemia) at time of transplantation. However, a recent study suggested using a sequential approach in this setting [29] . This latter attitude should be used in case of blasts count ≥10 %. Below this threshold, patients should be treated according to previous recommendations, with no additional chemotherapy preceding HSCT.
FA patients had an increased risk of experiencing acute GvHD when compared with patients with idiopathic aplastic anemia, leading to a substantially higher rate of treatment related mortality and for those patients who survive higher cumulative rate of cGVHD and higher risk of developing secondary malignancies [11, 16, 20] . An intense GvHD prophylaxis should thus be proposed. There is no evidence in the literature whether adding methotrexate or mycophenolate mofetil to cyclosporine A lead to better results. The use of antithymocyte globulins as an in vivo T-cell depletion method has been shown to dramatically reduce the incidence of acute GvHD while ex vivo T-cell depletion is currently under investigation [30] . However, these two attractive approaches deserve attention with respect to the potential risk of increasing the immune deficiency during the first month post-HSCT, leading to higher transplantation-related morbidity and mortality due to opportunistic infections and graft rejections, and should thus be reserved to the unrelated donor setting. Finally, it appears not safe to apply post-transplant cyclophosphamide technique in FA patients.
Severe congenital neutropenia (SCN) (excluding GATA-2 mutations)
Severe congenital neutropenia (SCN) is a rare and heterogeneous inherited hematologic disorder characterized by profound neutropenia diagnosed early in life and complicated by recurrent severe and life-threatening bacterial infections [31] . SCN is often caused by mutations of the ELA2 gene, HAX1 gene or, less frequently, of the GFI1 gene [32] [33] [34] [35] [36] . Other major complications are clonal evolution (leukemia and MDS), affecting about 10 % of patients [37] . The use of G-CSF therapy has radically changed patients' outcomes [38] . Allogeneic hematopoietic stem cell transplantation (HSCT) is still the only curative treatment for selected patients. Validated indications of transplantation include G-CSF resistance (>20 μg/kg/day) even in the absence of infections and clonal evolution [39] [40] [41] [42] .
In patients with neutropenia dependent on chronically high doses of G-CSF (at least 10 μg/kg per injection at least 3 months a year), HSCT should be discussed given the high risk of clonal evolution (Donadieu Haematologica 2005), especially in case of recurrent bacterial infections and if a matched family donor is available. Reported cases of SCN patients who have undergone HSCT include no more than 100 patients worldwide [43] . Because of the high heterogeneity of the published reports (different conditioning regimen, source of stem cells, donor type, disease stage at transplantation) and the small number of reported patients, it is difficult to draw general conclusions or recommendations.
However, as for FA patients and for any patient presenting IBMF, a healthy matched sibling donor is the best option. Matched (10/10) unrelated donor, as well as related 6/6 matched cord blood is also a reasonable option where mismatch unrelated donors (less than 10/10), haplo-identical HSCT, as well as the use of unrelated cord blood with 0, 1 or 2 HLA-disparities regardless of the number of cells should be done in experimented centers within clinical prospective trials only. To avoid an increased risk of GVHD, it is mandatory for using bone marrow as stem cell source. The great majority of published cases received a myeloablative conditioning regimen prior to the first HSCT, usually with busulfan and cyclophosphamide combination [40] . This regimen was effective, with rare graft failure and full chimerism was obtained for almost all patients. Treosulfan and thiotepa were also used. EBMT group recently reported the results from 136 SCN patents transplanted from 1990 and 2012. 61 were transplanted from matched related donor and 14 from mismatched donors. The 3-year overall survival was 82 % and TRM 17 %. In multivariate analysis, HSCT below 10 years of age from matched related or unrelated donor in the recent years appeared as good prognostic factors. Chronic GVHD cumulative incidence was significantly higher in patients transplanted with PBSC [41] . Less toxic, non-myeloablative, fludarabine-based, conditioning regimens might reduce transplanted-related mortality, but experience is still very little [44] . TBI should be avoided because of the risk of long-term complications.
In case of clonal evolution, the need for chemotherapy prior to HSCT is controversial [45] . Overall, this approach should be dedicated to patients with overt leukemia, but it can be deleterious in other patients (i.e., patients with MDS) as it may contribute to increasing infection risk [40, 43, 46, 47] . Ebihara, et al. described recently the evolution for 2 SCN patients transplanted for acute myeloid leukemia without prior intensive chemotherapy [48] .
Shwachman-diamond syndrome (SDS)
Shwachman-Diamond Syndrome (SDS) is a multisystemic autosomal recessive disorder, phenotypically heterogeneous characterized by exocrine pancreatic dysfunction, bone metaphyseal dysostosis, mild intellectual retardation, and variable neutropenia [49] . Almost all patients have a mutation in the SBDS gene located on chromosome 7 [50] . BMF and clonal evolution (Acute leukemia & MDS) are the main life-threatening complications. HSCT is currently the only potentially curative treatment for those patients. The major challenge is to identify patients who are at high risk of hematological complications and may benefit from HSCT. The French group proposed a classification of the severity of SDS based on the first blood counts (ANC < or ≥ 0.5 × 109/L; Hb < or ≥9 g/dL and platelet count < or ≥ 100 × 109/L) and on the age at diagnosis (< or ≥ 3 months). Patients diagnosed with SDS before the age of 3 months and with low values of hematologic parameters at diagnosis have a higher risk of major hematological complications than patients diagnosed after the age of 3 months and without low values of CBC, or with only one of these features. These results, once validated by future studies, will offer a simple way to identify patients, at time of diagnosis, at high risk of severe hematological complications who may be considered for HSCT [39, 51] .
Considering HSCT by itself, the recommendations are not different from SCN patients without SDS. However, complications from HSCT are more common in SDS patients than in patients with idiopathic blood dyscrasias [52] . However, some authors have proposed to use attenuated conditioning regimen has been proposed to limit toxicity [53] .
Diamond Blackfan anemia (DBA)
DBA is a autosomal dominant IBMF characterized by a non regenerative and often macrocytic anemia with erythroblastopenia. The penetrance was variable. Some patients present cranio-facial abnormalities in addition to BMF. Disease-causing mutations are identified in 40-45 % of patients and all involved genes code for ribosomal proteins. DBA patients may present higher risk of leukemia or MDS. During the first year of life, therapy is represented by regular transfusion program. After 12 months of age, steroids have to be tried, but only some patients experience response. The absence of response to steroids was defined the absence of reticulocyte count increase after two different periods of steroid therapy.
HSCT represents the only curative option. However, there is always the option of RBC transfusions in view of the relative easy chelation approach available today, and the option of transplant should be discussed with the family.
HSCT has to be proposed to steroid-refractory patients and may be discussed in patients responder, but dependant to steroid therapy above 0.3 mg/kg/d or transfusion dependant [54, 55] .
It appears better to perform HSCT before the age of 10 years and preferably between the ages of 2 and 5 years. There are enough data to recommend sibling donor as evidenced-based. There are too few reported cases with unrelated donor or mismatch donors (Haplo-identical or cord blood transplantation), then panel was not able to recommend any other type of donor than sibling. Bone marrow should thus be preferred to decrease the risk of chronic GVHD. There are few available data then the use of standard HSCT myeloablative conditioning regimen based on fludarabine and containing with Busulfan or Treosulfan and Thiotepa should be "recommended". TBI should be avoided because of the risk of long-term complications [39] .
Congenital amegakaryocytic thrombocytopenia (CAMT)
Congenital amegakaryocytic thrombocytopenia (CAMT) is an IBFM characterized by an absence of megakaryocytes in the bone marrow linked to mutation in c-MPL. This gene codes for thrombopoietin receptor. The inheritance pattern is autosomal recessive [56] . Severe form patients experience early pancytopenia onset. HSCT represents the only curative treatment. About 80 cases of HSCT in CAMT were registered in EBMT data base and were reported to the 2014 BMT tandem meetings in Dallas [57] . Some case reports or very short series were published at time.
Severe pancytopenia onset or clonal evolution (MDS or AML) appear as formal indications for HSCT. As for other IBMF syndromes, matched healthy sibling donor is the best option. Matched (10/10) unrelated donor, as well as related 6/6 matched cord blood is also a reasonable option where mismatched unrelated donors (less than 10/10), haplo-identical HSCT, as well as the use of unrelated cord blood with 0, 1 or 2 HLA-disparities regardless of the number of cells should be done in experimented centers within clinical prospective trials only.
IN the EBMT-cohort presented during the 2014 BMT tandem meetings, then the rate of primary graft failure appeared higher than expected for bone marrow failure. Standard myeloablative procedure based on fludarabine and either busulfan or treosulfan is recommended in case of either clonal evolution or isolated thrombocytopenia or allo-immunization [58] .
Dyskeratosis congenita (DC)
Dyskeratosis congenita is a rare BMF syndrome characterized by a triad (reticulated skin hyperpigmentation, nail dystrophy and oral leukoplakia). Telomerase dysfunction, ribosome deficiency and protein biosynthesis are responsible for this disorder. Until now, HSCT has shown disappointing results mainly because of severe late effects, including graft failure, GvHD, sepsis and, more importantly the increased propensity to develop organ toxicity, namely pulmonary fibrosis, hepatic cirrhosis and veno-occlusive disease, among others [59] [60] [61] . Total body irradiation and busulfan should not be used in this setting because of the high risk of toxicity. Mismatch related or unrelated donors are still associated with a worse prognosis than HSCT from a sibling donor [62] . Fludarabine-containing non-myeloablative conditioning regimens are now increasingly used and might give better short-term results [63] [64] [65] [66] . The literature is scarce on the subjects to draw strong statements.
BMF syndromes occur in 80 % of cases and represent the main indication for HSCT. Clonal evolution (MDS or AML) is also common with DC, because of cancer predisposition [67] . A matched healthy sibling donor appears as the best option. Matched (10/10) unrelated donor, as well as related 6/6 matched cord blood is also acceptable.
Mismatch unrelated donors (less than 10/10), haploidentical HSCT, as well as the use of unrelated cord blood with 0, 1 or 2 HLA-disparities regardless of the number of cells should be done only in experimented centers within clinical prospective trials.
This hypersensitivity to irradiation and chemotherapy translated into poor survival of patients after HSCT, using conventional standard conditioning regimen [68, 69] . Fludarabine-containing non-myeloablative conditioning regimens are now increasingly used and might give better short-term results [64] [65] [66] 70] . The overall data suggest long-term surveillance is important particularly for cancers and pulmonary complications both of which are likely to be secondary to the genetic defect that is not corrected by HSCT.
Conclusion
The group of IBMF syndromes contains a wide disease spectrum and interests few patients. The phenotypical heterogeneity associated with extra-medullary abnormalities has to be carefully evaluated before any HSCT indication since transplantation may only correct impaired hematopoiesis. If HSCT is indicated, transplantation has to be done before transfusion dependency preferentially from healthy sibling donor bone marrow. For those IBMF with clonal evolution risk, yearly marrow evaluation has to be performed and HSCT done before MDS/acute leukemia occurrence.
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